Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis

Nature Communications

Volumn 5, Issue , 2014, Pages

  Liu, Yongqing ^a,b   Lu, Xiaoqin ^b   Huang, Li ^b,c   Wang, Wei ^b   Jiang, Guomin ^b   Dean, Kevin C ^b   Clem, Brian ^a   Telang, Sucheta ^a   Jenson, Alfred B ^a   Cuatrecasas, Miriam ^d,e   Chesney, Jason ^a   Darling, Douglas S ^f   Postigo, Antonio ^a,e,g   Dean, Douglas C ^a,b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c ZHEJIANG UNIVERSITY   (China)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f UNIVERSITY OF LOUISVILLE   (United States)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; HOMEODOMAIN PROTEIN; KRAS2 PROTEIN, MOUSE; KRUPPEL LIKE FACTOR; PROTEIN P21; PTEN PROTEIN, MOUSE; ZEB1 PROTEIN, MOUSE;

CANCER; CELL ORGANELLE; NUMERICAL MODEL; THRESHOLD; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; LUNG ADENOCARCINOMA; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; PRECANCER; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; ADENOCARCINOMA; ADENOMA; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; ADENOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; RNA, MESSENGER;

EID: 84922566848     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6660     Document Type: Article

References (52)

1. Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310 (2007).
2. Castellano, E. et al. Requirement for interaction of PI3-kinase p110a with RAS in lung tumor maintenance. Cancer Cell 24, 617-630 (2013).
3. Cully, M. et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192 (2006).
4. Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296 (2012).
5. Brabletz, S. & Brabletz, T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer EMBO Rep. 11, 670-677 (2010).
6. Lamouille, S., Xu, J. & Denryck, R. Molecular mechanisms of epithelialmesenchymal transitions. Nat. Rev. Mol. Cell Biol. 15, 178-196 (2014).
7. Shin, S. et al. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 38, 114-127 (2010).
8. Liu, Y. et al. Sequential inductions of the ZEB1 transcription factor caused by mutation of Rb and the Ras proteins are required for tumor initiation and progression. J. Biol. Chem. 288, 11572-11580 (2013).
9. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008).
10. Liu, Y., El-Naggar, S., Darling, D. S., Higashi, Y. & Dean, D. C. ZEB1 links epithelial-mesenchymal transition and cellular senescence. Development 135, 579-588 (2008).
11. Liu, Y. et al. Rb1 family mutation is sufficient for sarcoma initiation. Nat. Commun. 4, 2650 (2013).
12. Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61-74 (2013).
13. Liu, Y. et al. Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell 4, 336-347 (2009).
14. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
15. Takagi, T. et al. DeltaEF1, a zinc finger and homeodomain transcription factor, is required for skeleton patterning in multiple lineages. Development 125, 21-31 (1998).
16. Liu, Y. et al. ZEB1 mutant mice as a model of posterior corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 49, 1843-1849 (2008).
17. Liskova, P. et al. Further genetic and clinical insights into posterior polymorphous coreal dystrophy 3. JAMA Ophthalmol. 131, 1296-1303 (2013).
18. Karreth, F. A. et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147, 382-395 (2011).
19. Knobbe, C. B. et al. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27, 5398-5415 (2008).
20. Oh, W. J. & Jacinto, E. mTOR complex 2 signaling and functions. Cell Cycle 10, 2305-2316 (2011).
21. Magee, J. A. et al. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11, 415-428 (2012).
22. Travis, W. D. et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244-285 (2011).
23. Gemmill, R. M. et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 300, 66-78 (2011).
24. Ckow, J. Y. et al. ras/erk modulates tgf-beta-regulated pten expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28, 2321-2327 (2007).
25. Toonkel, R. L. et al. Tgf-beta signaling pathway in lung adenocarcinoma invasion. J. Thorac. Oncol. 5, 153-157 (2010).
26. Gregory, P. A. et al. An autocrine TGF-beta/seb/mir-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 22, 1686-1698 (2011).
27. Ahn, Y. H. et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J. Clin. Invest. 122, 3170-3183 (2012).
28. Young, N. P. et al. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res. 71, 4040-4047 (2011).
29. Yoo, J. et al. H-Ras and K-Ras gene mutations in primary human soft tissue sarcoma: concomitant mutations in the ras genes. Mod. Pathol. 12, 775-780 (1999).
30. Kawaguchi, K. et al. Genetic and epigenetic alterations of the pten gene in soft tissue sarcomas. Hum. Pathol. 36, 357-363 (2005).
31. Geryk-Hall, M. & Hughes, D. P. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr. Oncol. Rep. 11, 446-453 (2009).
32. Mora, J. et al. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatr. Bood Cancer 58, 532-538 (2012).
33. Trimboli, A. J. et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461, 1084-1091 (2009).
34. Serrano, M. et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
35. Ho, V. M. et al. The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene 28, 1393-1399 (2009).
36. Harbour, J. W. & Dean, D. C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14, 2393-2409 (2000).
37. Sage, J. et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortilization. Genes Dev. 14, 3037-3050 (2000).
38. Liu, Y. et al. The zinc finger transcription factor, ZFHX1A, is linked to cell proliferation by Rb/E2F1. Biochem. J. 408, 79-85 (2007).
39. Arima, Y. et al. Induction of ZEB proteins by induction of RB protein is key determinant of mesenchymal phenotype of breast cancer. J. Biol. Chem. 287, 7896-7906 (2012).
40. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
41. Zhou, J. et al. Activation of the pten/mtor, stat3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA 104, 16158-16163 (2007).
42. Bronisz, A. et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat. Cell Biol. 14, 159-167 (2011).
43. Hopkins, B. D. et al. A secreted pten phosphatase that enters cells to alter signaling and survival. Science 341, 399-402 (2013).
44. El-Naggar, S., Liu, Y. & Dean, D. C. Mutation of the Rb1 pathway leads to overexpression of mTor, constitutive phosphorylation of Akt on serine 473, resistance to anoikis and a block in c-Raf activation. Mol. Cell. Biol. 29, 5710-5717 (2009).
45. Dey, N. et al. tgfb-stimulated microRNA-21 utilizes PTEN to orchestrate akt/mtorc1 signaling for mesangial hypertrophy and matrix expansion. PLoS ONE 7, e42316 (2012).
46. Escriva, M. et al. Repression of pten phosphatase by snail1 transcription factor during gamma radiation-induced apoptosis. Mol. Cell. Biol. 28, 1528-1540 (2008).
47. Smit, M. A. & Peeper, D. S. ZEB1 is required for Trkb-induced epithelialmesenchymal transition, anoikis resistance and metastasis. Oncogene 30, 3735-3744 (2011).
48. Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342, 1234850 (2013).
49. Meuwissen, R. & Berns, A. Mouse models for human lung cancer. Genes Dev. 19, 643-664 (2005).
50. Dong, P. et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition though modulation of the miR-130b-ZEB1 axis. Oncogene 32, 3286-3295 (2013).
51. Kim, T. et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 208, 875-883 (2011).
52. Takeuchi, T. et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J. Clin. Oncol. 24, 1679-1685 (2006).